Objective:

To highlight emerging therapeutic innovations for wet age-related macular degeneration (AMD) and address the significant unmet needs in its management.

Key Findings:

• Current anti-VEGF therapies do not neutralize all VEGF isoforms and have a high treatment burden, impacting patient quality of life.
• TKIs offer a multi-target approach that may improve long-term outcomes and reduce treatment frequency, potentially enhancing patient adherence.
• Sustained-release formulations of TKIs are in advanced clinical development and show promise in reducing retinal fluid fluctuations, which can lead to better visual stability.

Interpretation:

The advancements in TKI therapies and sustained-release technologies represent a significant shift in wet AMD management, potentially leading to better patient outcomes, reduced treatment burden, and improved quality of life.

Limitations:

• The long-term efficacy and safety of new therapies are still under investigation, and potential adverse effects remain a concern.
• Current studies may not fully represent diverse patient populations, limiting the generalizability of findings.

Conclusion:

Innovative therapies like TKIs and sustained-release systems may reshape the management of wet AMD, aiming for improved vision preservation, reduced treatment frequency, and highlighting the need for ongoing research and patient monitoring.